SCHEMBL7160069

SCHEMBL7160069

CCN(CC)CCN(CCN(CC)CC)c1ccccc1-c1nc2ccncc2n1C(C)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
TSHR P16473 1/20 0.37
PDE2A O00408 2/20 0.36
PDE4D Q08499 1/20 0.36
PDE11A Q9HCR9 1/20 0.36
PDE10A Q9Y233 1/20 0.36
PKM P14618 1/20 0.36
USP2 O75604 1/20 0.35
DRD2 P14416 5/20 0.34
DRD3 P35462 5/20 0.34
ATM Q13315 1/20 0.34
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7155951 0.92 NPC1 (0.40) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL7155784 0.88 PKM (0.44) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL7159437 0.86 NPC1 (0.42) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL7552014 0.85 RPS6KA5 (0.45) KDM4EALDH1A1HPGDPDE2APDE4D
SCHEMBL7152128 0.81 CYP1A2 (0.36) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL7160902 0.81 ALDH1A1 (0.49) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL7156642 0.81 KDM4E (0.38) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL7153769 0.79 HDAC1 (0.39) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL7160121 0.79 NPC1 (0.53) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL7553122 0.78 RPS6KA5 (0.56) KDM4EALDH1A1HPGDHSD17B10PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6534521-B2 Useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection MILLENNIUM PHARMACEUTICALS, INC. 2003-03-18 US disclosed
US-6348487-B1 ANTIINFLAMMATORY AGENTS, ATHEROSCLEROSIS, RESTINOSIS AND IMMUNE DISORDERS MILLENNIUM PHARMACEUTICALS, INC. 2002-02-19 US disclosed
US-6184235-B1 MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) ANTAGONIST FOR TREATMENT OF INFLAMMATORY DISEASES, ATHEROSCLEROSIS, RESTENOSIS, AUTOIMMUNE DISEASES, ORGAN TRANSPLANT REJECTION IN MAMMALS WARNER-LAMBERT COMPANY 2001-02-06 US disclosed
EP-0927167-A1 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1999-07-07 EP disclosed
WO-1998006703-A1 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1998-02-19 WO disclosed